← Eichor
Condition: Classical Hodgkin Lymphoma Refractory Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Classical Hodgkin Lymphoma Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 · 18 location(s) · Canadian Cancer Trials Group · NCT05180097PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 · 4 location(s) · St. Petersburg State Pavlov Medical University · NCT06812858MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT06377540Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 2 · 5 location(s) · City of Hope Medical Center · NCT04561206A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT04510636Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/Phase 2 · 6 location(s) · Veronika Bachanova · NCT03681561Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT06190067A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT06170489Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2 · 1 location(s) · University of Cologne · NCT04838652Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated W
Phase 2 · 2 location(s) · Emory University · NCT05039073Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Phase N/A · 12 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT06822855BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Phase 2 · 19 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT04378647
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.